Patent ID: 8404712

Claim:
A method for the treatment of a broncho-obstructive disease, comprising administering, to subject in need thereof, an effective amount, of a salt represented by formula (I): wherein: A is an optionally substituted aryl group, optionally substituted heteroaryl group, optionally substituted arylalkyl group, optionally substituted heteroarylalkyl group, or a group of formula (a) wherein: R 3 and R 4 are the same or different and are independently H, (C 3 -C 8 )-cycloalkyl, aryl or heteroaryl, wherein said aryl or heteroaryl may be optionally substituted with a halogen atom or with one or more substituents independently selected from the group consisting of OH, O—(C 1 -C 10 )-alkyl, oxo, SH, S—(C 1 -C 10 )-alkyl, NO 2 , CN, CONH 2 , COOH, (C 1 -C 10 )-alkoxycarbonyl, (C 1 -C 10 )-alkylsulfanyl, (C 1 -C 10 )-alkylsulfinyl, (C 1 -C 10 )-alkylsulfonyl, (C 1 -C 10 )-alkyl, and (C 1 -C 10 )-alkoxyl or when R 3 and R 4 are both independently aryl or heteroaryl they may be linked through a Y group which is a (CH 2 ) n group wherein n=0-2, wherein when n=0, Y is a single bond, forming a tricyclic ring system wherein a carbon atom of (CH 2 ) n may be substituted by heteroatom selected from O, S, N, and with the proviso that R 3 and R 4 are never both H; R is a group selected from the group consisting of: (C 1 -C 10 )-alkyl, (C 2 -C 10 )-alkenyl, and (C 2 -C 10 )-alkynyl each of which may be optionally substituted with a group selected from the group consisting of: NH 2 , NR 1 R 2 , CONR 1 R 2 , NR 2 COR 1 , OH, SOR 1 , SO 2 R 1 , SH, CN, NO 2 , an alicyclic compound, Z—R 1 , wherein Z is selected from CO, O, COO, OCO, SO 2 , S, SO, COS, and SCO or it is a bond, and (C 3 -C 8 )-cycloalkyl; R 1 is a group selected from the group consisting of: an alicyclic compound optionally substituted with one or more substituents independently selected from the group consisting of OH, oxo, SH, NO 2 , CN, CONH 2 , NR 2 CO—(C 1 -C x )-alkyl, COOH, (C 1 -C 10 )-alkoxycarbonyl, (C 1 -C 10 )-alkylsulfanyl, (C 1 -C 10 -alkylsulfinyl, (C 1 -C 10 )-alkylsulfonyl, (C 1 -C 10 )-alkyl, and (C 1 -C 10 )-alkoxyl NR 2 CO—(C 1 -C 10 )-alkyl; an aryl group optionally substituted with NR 2 CO—(C 1 -C 10 )-alkyl; and a heteroaryl group optionally substituted with a group selected from the group consisting of NR 2 CO—(C 1 -C 10 )-alkyl, (C 1 -C 10 )-alkyl, O—(C 1 -C 10 )-alkyl, and halogen, R 2 is a group selected from the group consisting of H, phenoxycarbonyl, benzyloxycarbonyl, (C 1 -C 10 )-alkoxycarbonyl, (C 1 -C 10 )-alkylcarbonyl, (C 1 -C 10 )-alkylsulfonyl; and (C 1 -C 10 )-alkyl and X − is a physiologically acceptable anion.